Collegium Pharmaceutical’s (COLL) Neutral Rating Reiterated at Piper Sandler

Piper Sandler restated their neutral rating on shares of Collegium Pharmaceutical (NASDAQ:COLL) in a research note published on Friday morning, Benzinga reports. They currently have a $37.00 price objective on the specialty pharmaceutical company’s stock.

Several other analysts also recently commented on COLL. HC Wainwright upped their price objective on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a buy rating in a report on Thursday, September 5th. StockNews.com lowered shares of Collegium Pharmaceutical from a strong-buy rating to a buy rating in a report on Saturday, August 31st. Needham & Company LLC reiterated a hold rating on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. Finally, Truist Financial upped their target price on Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a buy rating in a research note on Friday, August 9th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Collegium Pharmaceutical currently has a consensus rating of Moderate Buy and a consensus price target of $42.60.

Collegium Pharmaceutical Price Performance

NASDAQ COLL opened at $37.72 on Friday. The company has a market cap of $1.23 billion, a price-to-earnings ratio of 15.72 and a beta of 0.94. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.11 and a quick ratio of 1.04. The stock’s fifty day moving average price is $37.27 and its 200 day moving average price is $35.48. Collegium Pharmaceutical has a 1 year low of $20.95 and a 1 year high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.22. Collegium Pharmaceutical had a return on equity of 107.62% and a net margin of 17.32%. The business had revenue of $145.28 million for the quarter, compared to analyst estimates of $143.94 million. During the same period in the prior year, the company earned $1.13 earnings per share. The company’s revenue was up 7.2% on a year-over-year basis. As a group, equities research analysts forecast that Collegium Pharmaceutical will post 5.79 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Thomas B. Smith sold 9,593 shares of the firm’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $36.62, for a total transaction of $351,295.66. Following the sale, the executive vice president now directly owns 53,816 shares in the company, valued at $1,970,741.92. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, EVP Shirley R. Kuhlmann sold 19,248 shares of the business’s stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $38.30, for a total value of $737,198.40. Following the completion of the sale, the executive vice president now directly owns 120,161 shares in the company, valued at $4,602,166.30. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Thomas B. Smith sold 9,593 shares of the stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $36.62, for a total value of $351,295.66. Following the transaction, the executive vice president now owns 53,816 shares in the company, valued at $1,970,741.92. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 3.98% of the company’s stock.

Hedge Funds Weigh In On Collegium Pharmaceutical

A number of large investors have recently added to or reduced their stakes in COLL. Gladius Capital Management LP purchased a new stake in shares of Collegium Pharmaceutical during the second quarter worth about $32,000. nVerses Capital LLC increased its stake in Collegium Pharmaceutical by 1,600.0% during the 2nd quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock worth $55,000 after buying an additional 1,600 shares in the last quarter. GAMMA Investing LLC increased its stake in Collegium Pharmaceutical by 124.5% during the 3rd quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock worth $55,000 after buying an additional 792 shares in the last quarter. CWM LLC raised its holdings in shares of Collegium Pharmaceutical by 97.5% during the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock valued at $58,000 after acquiring an additional 736 shares during the last quarter. Finally, Sheaff Brock Investment Advisors LLC purchased a new position in shares of Collegium Pharmaceutical in the first quarter valued at approximately $204,000.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.